Tata Group and Singapore International Airlines joint venture company could...
A recent study has found that the patients suffering from the advanced stage of lung cancer can be cured if they are provided with the combined treatment of chemotherapy and TG4010 immunotherapy. The findings of the study have been published in the Lancet Oncology journal.
During the research, the researchers found that if the patients are treated with the combination of the two therapies for a period of six months then the cancer can be cured. According to the researchers, the TG4010 therapy increases the effect of chemotherapy.
Following the findings of the study, it is now being recommended that the pharmaceutical companies and the TG4010 manufactures should join their hands so that the lung cancer patients could be treated effectively.
Although it has been found that the chemotherapy and the TG4010 therapy can be effective in treating lung cancer patients, further study is required to be conducted. Commenting upon the findings of the study, the Srikumar Chellappan from the National Functional Genomics Center said that the finding would help in paving way for an effective treatment.
As a standard treatment, the lung cancer patients are provided with chemotherapy alone, which was though not so successful in easing up the agony of the patients. Chellappan said, "It should be pointed out that the increases in overall survival and progression-free survival are not dramatic, but any increase is very welcome, considering that the patients are in an advanced stage of cancer".
It has been informed that the combined treatment could prove beneficial for those patients whose immune system have "natural killer cells". Moreover, the combined treatment of chemotherapy and TG4010 therapy could leave serious side effects on the body of the patient.
There are millions of lung cancer patients all over the world who fail to survive as they are not provided with timely care. It is hoped that the findings of the study would help in saving the innocent lives.